Abstract Number: 0654 • ACR Convergence 2020
The Effects of Dietary Macronutrients on Serum Urate: A Secondary Analysis of the OmniHeart Trial
Background/Purpose: Diet is a significant determinant of hyperuricemia and risk for gout. Dietary recommendations to prevent gout emphasize reducing purine intake; however, low-purine diets are…Abstract Number: 0655 • ACR Convergence 2020
Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial
Background/Purpose: Despite scarce evidence regarding the effects of weight loss in gout1, international guidelines recommend dietary advice and weight loss as a core management strategy…Abstract Number: 0656 • ACR Convergence 2020
A Sugar Tax Results in Reduced Incident Gout, Quality Adjusted Life Years Lost and Economic Cost from Gout: A Health Economic Analysis
Background/Purpose: Intake of sugar is associated with increased incident gout. Sugar taxes have been effective at reducing the intake of sugar in several jurisdictions. We…Abstract Number: 0657 • ACR Convergence 2020
Gout and Heart Failure in the US
Background/Purpose: Heart failure (HF) is the eighth leading cause of death in the US, with a 38% increase in the number of deaths due to…Abstract Number: 0658 • ACR Convergence 2020
Identification of Two Novel Dysfunctional Variants in a Physiologically Important Urate Transporter ABCG2 in Paediatric-onset Familial Hyperuricemia and Gout Patients in Three Generations
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…Abstract Number: 0659 • ACR Convergence 2020
Polynesian-Specific Gout-Associated Frameshift Variant in PRPSAP1
Background/Purpose: Polynesian (NZ Māori and Pacific) populations have increased prevalence of gout. Hyperuricaemia is contributed to by increased urate production in the liver via the…Abstract Number: 0660 • ACR Convergence 2020
Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk for Gout – a Comparison Among Canagliflozin, Dapagliflozin and Empagliflozin
Background/Purpose: Sodium-glucose co-transporter-2 inhibitors (SGLT2-i) are anti-diabetic drugs that have a urate-lowering effect. SGLT2-i had a more favorable impact on gout risk than glucagon-like peptide-1…Abstract Number: 0661 • ACR Convergence 2020
Genomic Regions Jointly Associated with eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Kidney Disease
Background/Purpose: Gout and hyperuricemia (HU), serum urate (SU) > 6.8 mg/dL, often present in the context of chronic kidney disease. It has long been known…Abstract Number: 0662 • ACR Convergence 2020
Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study
Background/Purpose: Gout is the most common type of inflammatory arthritis, with a prevalence in the Veteran’s Health Administration (VHA) of nearly 6%. While gout flares…Abstract Number: 0663 • ACR Convergence 2020
Analysis of Common Gout Comorbidities in the UK Biobank Cohort Reveals Sex-Specific Effects and Genetic Differentiation
Background/Purpose: This study aimed to estimate the extent to which gout associated genetic variants are associated with the presence/absence of common comorbidities in gout patients…Abstract Number: 0664 • ACR Convergence 2020
Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction
Background/Purpose: Hyperuricemia (HUC) has been shown to have an impact in the left atrium and left ventricle remodeling leading to the development of heart failure…Abstract Number: 0665 • ACR Convergence 2020
Trends in Immunomodulation/pegloticase Co-therapy from 2015-2019: A Claims Database Study
Background/Purpose: Pegloticase, a recombinant, PEGylated uricase enzyme, is used to treat uncontrolled gout in patients who do not improve on or are intolerant of oral…Abstract Number: 0666 • ACR Convergence 2020
Identification of Intracellular Vacuoles in Synovial Fluid with Calcium Pyrophosphate and Monosodium Urate Crystals
Background/Purpose: Synovial fluid analysis using polarized microscopy is the gold standard for the diagnosis of crystal-related arthritis. In our experience, we have noted that, when…Abstract Number: 0667 • ACR Convergence 2020
Gout Management Beyond Prescription Writing: The Role of the Pharmacist
Background/Purpose: Urate lowering therapy (ULT) is recommended for long-term gout management. However, gout flares are common at the time of starting ULT, and these flares…Abstract Number: 0668 • ACR Convergence 2020
Outcomes and Resource Utilization After Total Knee Arthroplasty in Calcium Pyrophosphate Crystal Deposition Disease Patients: Insights from the National Inpatient Sample Database
Background/Purpose: Total knee arthroplasty (TKA) is one of the most frequently performed orthopedic procedures in patients with joint cartilage destruction. Calcium pyrophosphate crystal deposition (CPPD)…
- « Previous Page
- 1
- …
- 878
- 879
- 880
- 881
- 882
- …
- 2607
- Next Page »
